anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: In patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock, primary percutaneous coronary intervention (pPCI) is the preferred revascularization option. Little is known about the efficacy and safety of a pharmacoinvasive approach for patients with cardiogenic shock presenting to a non-PCI hospital with prolonged interhospital transport times.
METHODS: In a retrospective analysis of geographically extensive ST-segment-elevation myocardial infarction network (2006-2021), 426 patients with cardiogenic shock and ST-segment-elevation myocardial infarction presented to a non-PCI-capable hospital and underwent reperfusion therapy (53.8% pharmacoinvasive and 46.2% pPCI). The primary clinical outcome was a composite of in-hospital mortality, renal failure requiring dialysis, cardiac arrest, or mechanical circulatory support, and the primary safety outcome was major bleeding defined as an intracranial hemorrhage or bleeding that required transfusion was compared in an inverse probability weighted model. The electrocardiographic reperfusion outcome of interest was the worst residual ST-segment-elevation.
RESULTS: Patients with pharmacoinvasive treatment had longer median interhospital transport (3 hours versus 1 hour) and shorter median symptom-onset-to-reperfusion (125 minute-to-needle versus 419 minute-to-balloon) times. ST-segment resolution ≥50% on the postfibrinolysis ECG was 56.6%. Postcatheterization, worst lead residual ST-segment-elevation <1 mm (57.3% versus 46.3%; P=0.01) was higher in the pharmacoinvasive compared with the pPCI cohort, but no differences were observed in the worst lead ST-segment-elevation resolution ≥50% (77.4% versus 81.8%; P=0.57). The primary clinical end point was lower in the pharmacoinvasive cohort (35.2% versus 57.0%; inverse probability weighted odds ratio, 0.44 [95% CI, 0.26-0.72]; P<0.01) compared with patients who received pPCI. An interaction between interhospital transfer time and reperfusion strategy with all-cause mortality was observed, favoring a pharmacoinvasive approach with transfer times >60 minutes. The incidence of the primary safety outcome was 10.1% in the pharmacoinvasive arm versus 18.7% in pPCI (adjusted odds ratio, 0.41 [95% CI, 0.14-1.09]; P=0.08).
CONCLUSIONS: In patients with ST-segment-elevation myocardial infarction presenting with cardiogenic shock and prolonged interhospital transport times, a pharmacoinvasive approach was associated with improved electrocardiographic reperfusion and a lower rate of death, dialysis, or mechanical circulatory support without an increase in major bleeding.
This is a randomized controlled trial. Patients suffering from recurrent acute sinusitis episodes will be randomly allocated to two groups: intervention group, where they will receive endoscopic sinus surgery in addition to medical treatment and control group, where they will receive mere medical treatment. Both groups will be followed-up for 5 to 6 months. At baseline and after 5 to 6 months, patients will answer the life quality questionnaires SNOT-22 and RAND 36-item Health Survey. The numbers of sinusitis episodes, medical appointments for respiratory symptoms, use of medications, numbers of days lost from work or studies and numbers of days with various respiratory and adverse symptoms will be recorded with patient diaries. The potential serious adverse events (e.g. cerebrospinal fluid leak, orbital complications) related to surgery will be collected from the medical records.
Body mass index (BMI; weight (kg)/height (m)2) is commonly used to measure general adiposity. However, evidence of its appropriateness for males and females remains inconsistent. We aimed to identify the most appropriate sex-specific power value that height should be raised to in the formula and the value that would make it achieve height independency and body fatness dependency. We randomly assigned UK Biobank participants recruited in the United Kingdom between 2006 and 2010 (n = 489,873; mean age = 56.5 years; 94.2% White) to training and testing sets (80%:20%). Using height raised to the power of -50.00 to 50.00, we identified the optimal power value that either minimized correlation with height or maximized correlation with body fat percentage, using age-adjusted correlations. The optimal power values for height were 1.77 for males and 1.39 for females. The new formulas resulted in 4.5% of females and 2.4% of males being reclassified into a different BMI category. The formulas did not show significant improvement (in terms of area under the receiver operating characteristic curve, sensitivity, and specificity) in identifying individuals with excessive body fat percentage or in predicting risk of all-cause mortality. Therefore, the conventional BMI formula is still valuable in research and disease screening for both sexes.
A nationally representative sample of 4753 non-institutionalized adults aged 18 years or older from the Spanish population was collected (with an over-sampling of people aged 50+ years). A multi-stage clustered design was employed. A total of 2528 individuals were re-interviewed in 2014. In 2018, 1577 were again evaluated. Finally, in 2022, 963 participants took part of another study's evaluation.
Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
Human cells possess many different polymerase enzymes, which collaborate in conducting DNA replication and genome maintenance to ensure faithful duplication of genetic material. Each polymerase performs a specialized role, together providing a balance of accuracy and flexibility to the replication process. Perturbed replication increases the requirement for flexibility to ensure duplication of the entire genome. Flexibility is provided via the use of error-prone polymerases, which maintain the progression of challenged DNA replication at the expense of mutagenesis, an enabling characteristic of cancer. This review describes our recent understanding of mechanisms that alter the usage of polymerases during tumorigenesis and examines the implications of this for cell survival and tumor progression. Although expression levels of polymerases are often misregulated in cancers, this does not necessarily alter polymerase usage since an additional regulatory step may govern the use of these enzymes. We therefore also examine how the regulatory mechanisms of DNA polymerases, such as Rad18-mediated PCNA ubiquitylation, may impact the functionalization of error-prone polymerases to tolerate oncogene-induced replication stress. Crucially, it is becoming increasingly evident that cancer cells utilize error-prone polymerases to sustain ongoing replication in response to oncogenic mutations which inactivate key DNA replication and repair pathways, such as BRCA deficiency. This accelerates mutagenesis and confers chemoresistance, but also presents a dependency that can potentially be exploited by therapeutics.
Skin-peeling article consists of a cosmetically acceptable dry residue which contains abrasion particles, (I), having av. dia. 50-400 mu. Dry residue adheres uniformly to at least one part of a non-woven fibre fabric, fibres of which are opt. bonded to one another with a water-insoluble binder (II). Dry residue pref. contains and adhesive, (III), capable of being coarsely dispersed or colloidally distributed in water, to bond (I) adhesively on fabric surface in dry condition. Cosmetic skin-peeling by rubbing with wetted article, which is disposable, to remove dead facial skin-cells, cleanse and refine skin. Articles can be kept in ordinaly unsealed packs and resist prolonged storage in contact with air.
Rice (Oryza sativa) is one of the most important staple foods worldwide. However, rice blast disease, caused by the ascomycete fungus Magnaporthe oryzae, seriously affects the yield and quality of rice. Calmodulin-binding transcriptional activators (CAMTAs) play vital roles in the response to biotic stresses. In this study, we showed that OsCAMTA3 and CAMTA PROTEIN LIKE (OsCAMTAPL), an OsCAMTA3 homolog that lacks the DNA-binding domain, functioned together in negatively regulating disease resistance in rice. OsCAMTA3 associated with OsCAMTAPL. The oscamta3 and oscamtapl mutants showed enhanced resistance compared to wild-type plants, and oscamta3/pl double mutants showed more robust resistance to M. oryzae than oscamta3 or oscamtapl. An RNA-Seq analysis revealed that 59 and 73 genes, respectively, were differentially expressed in wild-type plants and oscamta3 before and after inoculation with M. oryzae, including OsALDH2B1, an acetaldehyde dehydrogenase that negatively regulates plant immunity. OsCAMTA3 could directly bind to the promoter of OsALDH2B1, and OsALDH2B1 expression was decreased in oscamta3, oscamtapl, and oscamta3/pl mutants. In conclusion, OsCAMTA3 associates with OsCAMTAPL to regulate disease resistance by binding and activating the expression of OsALDH2B1 in rice, which reveals a strategy by which rice controls rice blast disease and provides important genes for resistance breeding holding a certain positive impact on ensuring food security.
INTRODUCTION: Upper limb problems have a significant impact on the global population leading to pain and restricted joint mobility, ultimately impacting their quality of life. Traditional treatments, such as non-steroidal anti-inflammatory drugs and corticosteroids, often come with undesirable side effects, prompting patients to seek alternative therapies. In this trial, we hypothesise that soothing cream gel (SCG) will improve range of motion and chronic pain in the shoulder and elbow. The objective of this trial is to evaluate the efficacy of SCG in improving the range of motion and chronic pain in the shoulder and elbow.
METHODS AND ANALYSIS: A double-blinded, randomised, placebo-controlled trial is conducted to compare the effects of SCG and placebo gel. SCG contains Vitis vinifera essence, Melaleuca viridiflora essential oil, etc, and is manufactured according to Good Manufacturing Practice standards. The placebo gel will be processed with similar appearance, texture and scent but will lack active ingredients. 70 participants with upper limb problems will be recruited from four study sites, including clinical centres and a sport department at the Chinese University of Hong Kong (CUHK). Participants will be randomly assigned to either treatment group or placebo group for 2 weeks. Primary outcome will be the range of motion in the upper limb, assessed by a goniometer, to measure active flexion and abduction for the shoulder, and active flexion and extension for the elbow. The primary efficacy analyses will be based on the full analysis set following the intention-to-treat principle.
ETHICS AND DISSEMINATION: The trial has obtained approval from the joint CUHK-New Territories East Cluster (CRE-2023.142), and the patient enrolment commenced in July 2023. Written informed consent will be obtained from all participants prior to participation. Study results will be disseminated through publication in peer-reviewed journals and presentations at conference.
TRIAL REGISTRATION NUMBER: NCT05799391.
Methods, devices and systems for sharing information related to exercise/health activities are disclosed. A user terminal can acquire a device identifier associated with a health monitoring device, such as a monitoring wristband or a treadmill, through a communication program (e.g., an instant messaging application). The user terminal can communicate with a server of the communication program so that the server binds the device identifier with a user ID. The association of the user ID and the device identifier allows the user to share the health monitoring information from the health monitoring device with other users through the server. In addition, the connected users can participate in real-time competitions and share information related to the competition. The server also generates ranking lists or other sharing formats for the competition, improving user experience and making exercise and competition more attractive.
The invention provides a secret recipe for treating rectocele. To achieve the purpose of the invention, the secret recipe is composed of 500 ml of snow water, 300 g of dried fruit of a locust tree and brown sugar, wherein brown sugar is used as a guiding drug, and a small amount of brown sugar is added during administration of the secret recipe. The secret recipe comprises the following preparation steps: completely soaking 300 g of the fruit of the locust tree in 500 g of snow water for 30 and 40 d and storing an obtained product in shade, wherein the longer soaking time is, the better a therapeutic effect is. It is optimal that pericarp of the fruit of the locust tree is totally dissolved during soaking and the fruit swells due to soaking, a small amount of brown sugar is added as the guiding drug into snow water after soaking, and an obtained product can be directly taken. Water obtained after soaking of the fruit of the locust tree with snow water can be used for external application. An excellent effect is obtained through combined oral administration and external application of the water; rectal mucosal prolapse of rectocele and hyperemia, edema, hemorrhage, erosion and ulcer of rectal mucosa can be thoroughly, fundamentally and rapidly treated; and a treatment rate of 98% can be obtained in treatment of rectal mucosal prolapse, full-thickness rectal prolapse and prolapse of rectums and colon sigmoideum.
All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
A topical solution (may be a cream or gel or liquid) is disclosed for the treatment of acne lesion. The topical solution contains herbal extracts Dandelion (Taraxaci Mongolici Cum Radice Herba) in powder form approx. 0.5-5%, Senecio (Senecionis Scandens Herba) in powder form approx. 0.1-6%, Elephantopi (Elephantopus Scaber Herba) in powder form approx. 0.1-5%, Lonicera (Lonicerae Japanicae Flos) in powder form approx. 0.1-4%, Angelica (Fragrant Angelica) in powder form approx. 0.1-5%, Scute (Scutellariae Baicalensis Radix) in powder form approx 0.1-5%, Witch Hazel (Hamamelis Virginiana L.) in liquid form approx. 0.1-6% provides the action of killing bacteria, removal of inflammation and loosening of the blackheads of comedones in the pilosebaceous unit. The solution also contains transdermal agents includes Benzyl Alcohol approx. 0.1-5%, Propylene Glycol approx. 0.1-10%, Ethyl Alcohol 70% approx. 1-20% to facilitate penetration. The invention relates to herbal extract solution with transdermal agents for the use in the topical treatment of acne and other related inflammatory ailments. The invention further relates to methods of making and using the composition for the treatment of acne lesion.
The invention discloses a kind of beverage in winter helping and concentrating, be made up of by weight following component, 35 to 45 parts of Semen phaseoli radiati, Semen Nelumbinis 15 parts, 5 parts of the Radix Rehmanniae, Rhizoma Coptidis 0.5 part; Radix Adenophorae (Radix Glehniae) 8 parts; Herba Abri 2 parts; 8 parts of Fructus Benincasae; Bulbus Lilii 5 parts; Semen Sterculiae Lychnophorae 0.1 part; Cortex Lycii 3 parts; Herba Lysimachiae 3 parts; Spica Prunellae 5 parts; Semen Maydis 20 parts; Radix Ophiopogonis 5 parts; Rhizoma Polygonati Odorati 3 parts; Rhizoma Imperatae 3 parts; Flos Albiziae 1 part, Rhizoma Dioscoreae 10 parts, Fructus Lycii 5 parts, Radix Angelicae Sinensis 1 part; Pure water 1000 parts; Each component mixing draws beverage then through after filtering after boiling. The present invention is applicable to not be in the mood for, and the difficult personage sleeping, not being in the mood for sleep that sleeps less drinks, and clear efficacy is beneficial to teenager and tides over dry dynamic adolescence. Particularly suitable of the present invention is drunk in the winter time, has reached a fine balance. Can make that people is energetic, the mind is quiet. The invention also discloses the manufacture method of this kind of beverage. The manufacture method of this beverage, simply, cost is low, and equipment needed thereby is few.
1,178,191. Phenethylamine derivatives. KARL THOMAE G.m.b.H. 22 Sept., 1967 [22 Sept., 1966; 1 Feb., 1967; 15 Feb., 1967; 2 June, 1967; 5 Sept., 1967], No. 43327/67. Heading C2C. Novel phenethylamine derivatives of the general formula wherein each Hal is a bromine or chlorine atom; R 1  is a hydrogen atom or a hydroxyl group; R 2  and R 3  are each hydrogen atoms or C 1-4  alkyl radicals; and R 4  and R 5  are each hydrogen atoms or C 1-6  alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, phenyl, benzyl or adamantyl radicals, or R 4  and R 5 , together with the nitrogen atom to which they are attached, form a pyrrolidine, piperidine, piperazine, morpholine, hexamethyleneimine or camphidine ring, any of which rings may be substituted by C 1-3  alkyl radicals, and acid addition salts thereof are prepared (a) when R 4  and R 5  are not alkenyl or alkynyl radicals, by bromination or chlorination of the benzene ring of phenethylamines of the general formula wherein R is a hydrogen, chlorine, or bromine atom and R 4  and R 5  are as above defined, with the exception of alkenyl and alkynyl radicals; (b) when R 1  is a hydroxyl group, by reduction of ketones of the general formula with complex metal hydrides; (c) when R 1  is a hydrogen atom, by reduction of ketones of the third general formula above with hydrazine; (d) by reaction of phenethyl halides of the general formula wherein Hal<SP>1</SP> is a chlorine, bromine or iodine atom, with amines of the general formula R 4 R 5 NH; (e) by reduction of nitro-substituted phenethylamines of the general formula (f) by deacylation of acylarnino-substituted phenethylamines of the general formula wherein Ac is an acyl radical; (g) when R 1  is a hydroxyl group and R 2  and R 3  are hydrogen atoms and the H 2 N group is in the 2-position, by reduction of diketones of the general formula with complex metal hydrides; and (h) when R 1  is a hydroxyl group and R 2  and R 3  are hydrogen atoms and the H 2 N group is in the 2- position, by reduction of hydroxyketones of the general formula with complex metal hydrides; followed optionally by conversion of the product to an acid addition salt thereof. Pharmaceutical compositions having circulatory, analgesic, sedative, antipyretic, antiphlogistic, anti-tussive and/or broncholytic activity comprise, as active ingredient, at least one phenethylamine derivative of the first general formula above or non-toxic acid addition salt thereof, together with a pharmaceutical carrier or excipient, and may be administered orally, parenterally or rectally.
Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
PURPOSE: This study aimed to construct a prediction model regarding risk factors and prognostic factors for distant metastasis of T1-T3 stage rectal cancer. For this purpose, a population-based retrospective cohort study was conducted.
METHODS: Data on 7872 patients diagnosed with rectal cancer between 2004 and 2020 were obtained from the Surveillance, Epidemiology, and End Results database, of whom 746 had distant metastases at diagnosis. Independent risk factors for distant metastasis of rectal cancer were determined using univariate and multivariate logistic regression analyses. Cox proportional hazards regression analyses clarified the independent prognostic factors for distant metastases of rectal cancer. A 7:3 randomization process was used to place all patients into the training and internal validation groups. Furthermore, we retrospectively collected clinical data from 226 patients who had both rectal cancer and distant metastases between 2012 and 2024 at the Weifang Hospital of Traditional Chinese Medicine. We used the calibration curve, DCA curve, C-index, and area under the curve (AUC) to assess the discriminatory and pre-precision qualities of the models.
RESULTS: The multivariate logistic regression analysis identified race, tumor grade, T stage, N stage, radiotherapy, chemotherapy, surgery, tumor size, and histological subtype as risk factors for distant metastases in rectal cancer, with AUC values for both training and validation sets exceeding 0.8. Using Cox regression analysis, we determined that the age, sex, tumor size, surgery, chemotherapy, and radiotherapy were independent predictors of distant metastasis of rectal cancer. In the prognostic model, the C-index of the training cohort was 0.687 (95% CI: 0.6615-0.7125), that of the internal validation cohort was 0.692 (95% CI: 0.6508-0.7332), and that of the external validation cohort was 0.704 (0.6785-0.7295).
CONCLUSION: Our nomogram can predict risk factors and analyze the 1-, 2-, and 3 year prognosis of distant metastases in patients with rectal cancer, providing valuable guidance for future clinical work.
PURPOSE: An antibody-peptide fusion synergistic material is provided to function during diseases or progress of diseases. CONSTITUTION: An antibody-peptide fusion synergistic material contains an antibody and a biologically active peptide. The antibody and peptide function during disease occurrence or progress. The antibody and peptide function to each target. The antibody is an antibody or fragment thereof having binding activity for Ang-2. The peptide has binding activity for VEGF. A pharmaceutical composition contains the antibody-peptide fusion synergistic material as an active ingredient. The pharmaceutical composition is used for suppressing target function and cancer. A method for producing the antibody-peptide fusion synergistic material comprises: a step of inserting a nucleic acid molecule encoding the antibody-peptide fusion synergistic material to a vector; a step of introducing the vector to a host cell; and a step of culturing the host cells.